Cognitive decline in early Alzheimer’s disease patients can be slowed, and in some cases reversed, by a novel, personalized, integrative program designed by neurologist Dale E. Bredesen, MD from the Mary S. Easton Center for Alzheimer’s Disease Research, Department of Neurology, at the University of California, Los Angeles, and the Buck Institute for Research on Aging in Novato, California.
Dr. Bredesen’s study “Reversal of Cognitive Decline: A Novel Approach,” (AGING, September, 2014, Vol 6, No 9 , pp 707-717) shares 10 cases of early Alzheimer’s disease with cognitive impairment utilizing his MEND (metabolic enhancement for neurodegeneration) approach resulting in 9 of 10 having improvement in cognitive function, and 6 of 10 returning to work after having to stop work because of difficulties performing their work tasks. These positive results began to occur between 3-6 months after starting the program which initially evaluated 37 factors, or “network pieces” that all contribute to cognitive decline in Alzheimer’s disease. (see Table 1. Therapeutic System 1.0 in this article for a partial list assessment and treatment approaches).
Subjects in one of these four stages of Alzheimer’s disease have shown improvement with the MEND approach:
1. At risk but cognitive function is normal.
2. SCI – the individual has “Subjective Cognitive Impairment”. The subject knows that they are having problems with cognition but it doesn’t show up on any testing.
3. MCI – the individual has “Mild Cognitive Impairment”. The subject knows they are having problems with cognition and the tests show it. But their activities of daily living are not effected.
4. Alzheimer’s Disease – where the individual has SCI, MCI and they have problems with the activities of daily living (feeding, bathing, clothing themselves, etc.).
***Late Alzheimer’s disease has not shown benefit with the MEND approach in formal studies but there have been some isolated anecdotal reports of improvement.
There are three types of Alzheimer’s disease that this multifaceted approach addresses. All these three types of Alzheimer’s disease result in the body creating more amyloid deposits in the brain (hallmark of AD). There can also be individuals who have a mixture of these types caused by the following:
- Chronic inflammation and infection
- Trophic factor withdrawal (vitamin D deficiency, hormone deficiency, etc.)
- Challenge from toxins (i.e. mycotoxins, metals, etc.)
For more information on the “Bredesen Protocol for Alzheimer’s Disease” go to: www.drbredesen.com
Contact the The Buck Institute for Research on Aging, 8001 Redwood Blvd. Novato, CA 94945 T – 415-209-2206; F – 415- 209-2230.
Rowena S. Abulencia, Admin Lab Coordinator, The Buck Institute for Research on Aging, 8001 Redwood Blvd. Novato, CA 94945 T – 415-209-2206; F – 415- 209-2230, email: firstname.lastname@example.org www.thebuck.org
Be and Stay Well,
You may call Kirk Hamilton PA-C Monday thru Friday 8-9 a.m. PST at 916-489-4400 for brief medical questions at Health Associates Medical Group.